Skip to main content
Cash
Portfolio
TrendingMidtermsElectionsPoliticsSportsCultureCryptoCommoditiesClimateEconomicsMentions

Finance

Tech & Science
PredictLive118AccountSocial
MARKETSINVESTLIVE118

Industries

Financials odds and guides

IPO odds for every company
Product
Kalshi ProInvestMarketsIncentive programSmall business hedgingInstitutionsAPI & developers
Company
AboutKalshi ResearchBlogCareersPolicy CenterBrand Kit
Help
Help CenterFAQPrediction marketsFee scheduleTrading hoursRegulatoryTrust Center

© 2026 Kalshi Inc. · All rights reserved
PrivacyData Terms of ServiceTrading ProhibitionsFAQ for Finance Professionals
Trading on Kalshi involves risk and may not be appropriate for all. Members risk losing their cost to enter any transaction, including fees. You should carefully consider whether trading on Kalshi is appropriate for you in light of your investment experience and financial resources. Any trading decisions you make are solely your responsibility and at your own risk. Information is provided for convenience only on an "AS IS" basis. Past performance is not necessarily indicative of future results. Kalshi is subject to U.S. regulatory oversight by the CFTC.
All markets (679)
15 min (10)
Hourly (8)
Daily (11)
Weekly (2)
Monthly (49)
Annual (20)

Public Companies Hub
Indices
Foreign Exchange
Interest Rates
Company metrics
Company news
Industries
Biotech
Advertising Spend
Real Estate
Sector Trends
Match Ups

Austin, TX home values in November

Above $521,000
2.66x
Above $522,000
2.81x
$5,123 vol

Los Angeles, CA home values in November

Above $1.01 million
1.97x
Above $990,000
1.25x
$4,398 vol

Seattle, WA home values in November

Above $882,500
1.55x
Above $890,000
2.89x
$5,102 vol

Chicago, IL home values in November

Above $333,750
2.59x
Above $334,000
2.52x
$4,525 vol

Jersey City, NJ home values in November

Above $664,000
1.70x
Above $667,000
2.29x
$4,225 vol

Santa Monica, CA home values in November

Above $2.68 million
1.70x
Above $2.67 million
1.55x
$3,431 vol

Pacific Palisades, CA home values in November

Above $3.28 million
1.48x
Above $3.34 million
1.93x
$7,004 vol

Dallas, TX home values in November

Above $316,000
1.65x
Above $318,000
4.73x
$3,318 vol

Venice, CA home values in November

Above $2.05 million
2.09x
Above $2,055,000
1.97x
$2,752 vol

Philadelphia, PA home values in November

Above $224,250
2.19x
Above $224,750
2.19x
$2,453 vol

San Diego, CA home values in November

Above $1,122,500
1.67x
Above $1.12 million
1.46x
$1,925 vol

New York, NY home values in November

Above $875,000
1.93x
Above $877,500
2.24x
$1,750 vol

Palo Alto, CA home values in November

Above $3.91 million
1.65x
Above $3.95 million
2.66x
$4,802 vol

Phoenix, AZ home values in November

Above $415,000
1.73x
Above $412,000
1.40x
$1,096 vol

Miami, FL home values in November

Above $670,000
1.65x
Above $667,500
1.33x
$1,689 vol

Memphis, TN home values in December

Above $148,000
1.26x
Above $152,000
4.51x
$737 vol

FDA decision: Ralinepag by United Therapeutics (on or before June 24, 2027)

Yes
1.20x
No
3.96x
$41 vol

FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (this year)

Yes
1.12x
No
7.85x
$4,230 vol

FDA decision: Venglustat by Sanofi (this year)

Yes
1.16x
No
4.51x
$1,011 vol

FDA decision: Vamikibart by Genentech (on or before July 31, 2027)

Yes
1.44x
No
2.40x
$42 vol

FDA decision: Ulixacaltamide by Praxis Precision Medicines (on or before January 29, 2027)

Yes
1.28x
No
3.08x
$12 vol

FDA decision: Tozorakimab by AstraZeneca (on or before March 31, 2027)

Yes
1.23x
No
3.52x
$308 vol

FDA decision: Saroglitazar by Zydus Therapeutics (this year)

Yes
1.28x
No
3.29x
$1,707 vol

FDA decision: Lorundrostat by Mineralys Therapeutics (on or before December 22, 2026)

Yes
1.14x
No
4.73x
$70 vol